Amdisen Lau, Brink Carsten, Lorenzen Ebbe Laugaard, Roenlev Jeanette Dupont, Ewertz Marianne, Cronin-Fenton Deirdre
Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University and Aarhus University Hospital, Aarhus, Denmark.
Department of Clinical Research, University of Southern Denmark, Odense, Denmark.
Clin Epidemiol. 2025 Jan 25;17:41-49. doi: 10.2147/CLEP.S496579. eCollection 2025.
The thyroid gland is an organ at risk in breast cancer survivors who receive radiation therapy to the supraclavicular lymph nodes. We investigated the effect of radiation dose to the thyroid gland on the incidence of hypothyroidism in early-stage breast cancer patients treated with CT-guided radiation therapy.
We recruited women aged ≤75 years diagnosed with breast cancer from March 2016 through August 2017 at Odense University Hospital, Denmark. Thyroid function was measured in blood samples drawn at baseline, 6, 12, and 18 months. We delineated the thyroid gland using CT scans to estimate thyroid volume and radiation dose to the thyroid. Subclinical hypothyroidism was defined as a thyroid-stimulating hormone (TSH) level of >4 milli-international units per liter (mIU/l) in the presence of normal free thyroxine. We also conducted a subanalysis with a threshold resulting in approximately 20% events within the cohort. We used mixed logistic regression to estimate associations between radiation dose to the thyroid and subclinical hypothyroidism.
Among 102 patients, four developed subclinical hypothyroidism. There was no association between increasing radiation dose to the thyroid and incidence of subclinical hypothyroidism. However, a trend was observed suggesting that higher mean radiation dose to the thyroid was associated with elevated risk of subclinical hypothyroidism at a TSH threshold of >2.5mIU/l.
Using current reference levels, increasing radiation dose to the thyroid was not associated with subclinical hypothyroidism, but at lower TSH thresholds, radiation therapy may predispose to hypothyroidism.
甲状腺是接受锁骨上淋巴结放射治疗的乳腺癌幸存者中面临风险的器官。我们研究了甲状腺放射剂量对接受CT引导放射治疗的早期乳腺癌患者甲状腺功能减退发生率的影响。
我们招募了2016年3月至2017年8月在丹麦欧登塞大学医院诊断为乳腺癌的75岁及以下女性。在基线、6个月、12个月和18个月采集的血样中测量甲状腺功能。我们使用CT扫描勾勒出甲状腺,以估计甲状腺体积和甲状腺的放射剂量。亚临床甲状腺功能减退定义为在游离甲状腺素正常的情况下促甲状腺激素(TSH)水平>4毫国际单位/升(mIU/l)。我们还进行了一项亚分析,设定一个阈值,使队列中的事件发生率约为20%。我们使用混合逻辑回归来估计甲状腺放射剂量与亚临床甲状腺功能减退之间的关联。
在102例患者中,4例发生亚临床甲状腺功能减退。甲状腺放射剂量增加与亚临床甲状腺功能减退的发生率之间没有关联。然而,观察到一种趋势,即当TSH阈值>2.5mIU/l时,甲状腺平均放射剂量越高,亚临床甲状腺功能减退的风险越高。
根据目前的参考水平,甲状腺放射剂量增加与亚临床甲状腺功能减退无关,但在较低的TSH阈值下,放射治疗可能易导致甲状腺功能减退。